<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="80576">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01867047</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00037620</org_study_id>
    <secondary_id>Pro00037620</secondary_id>
    <nct_id>NCT01867047</nct_id>
  </id_info>
  <brief_title>ACE-Inhibitor Effects on Total Hip and Knee Arthroplasty Patients</brief_title>
  <official_title>Effects of Angiotensin Converting Enzyme Inhibitors on Total Hip and Knee Arthroplasty Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effects of Angiotension Converting Enzyme
      Inhibitors (ACE-I) during surgery and in the immediate postoperative period for patients
      undergoing elective total hip or knee arthroplasty.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>Change in blood pressure</measure>
    <time_frame>From baseline to discharge from hospital (approximately 6-8 weeks)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The number of instances of both mild (Systolic Blood Pressure less than 85 mmHG) and severe (Systolic Blood Pressure less than 65 mmHG) hypotension will be recorded.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of times vasopressors given to subject both intraoperatively and postoperatively</measure>
    <time_frame>Discharge from hospital (approximately 5 days)</time_frame>
    <safety_issue>No</safety_issue>
    <description>The number of times a vasopressors is provided to subjects will be recorded.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of instances subjects transferred to Intensive Care Unit (ICU)</measure>
    <time_frame>Discharge from hospital (approximately 5 days)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The number of instances that a subjects needs to be transferred to a step down unit or ICU will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of instances that subject receives allogeneic blood</measure>
    <time_frame>Discharge from hospital (approximately 5 days)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The number of instances that a subjects receives allogeneic blood will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of acute kidney injury</measure>
    <time_frame>Discharge from hospital (approximately 5 days)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of occurrences of acute kidney injury will be recorded.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Adverse Effects of Angiotensin-converting-enzyme Inhibitors</condition>
  <condition>Hypotension</condition>
  <arm_group>
    <arm_group_label>Continuation Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects randomized to this group will continue their ACE-I through the day of surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cessation Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects randomized to this group will stop their ACE-I two days prior to surgery (last dose &gt;48 hours prior to surgery)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cessation group</intervention_name>
    <description>Subjects stop ACE-I 48 hours prior to surgery</description>
    <arm_group_label>Cessation Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Continuation group</intervention_name>
    <description>Subjects take ACE-I through day of surgery</description>
    <arm_group_label>Continuation Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients electing to undergo primary or revision total hip or knee arthroplasty

          -  Currently taking an ACE-I

        Exclusion Criteria:

          -  Trauma patients

          -  Immunosuppressed patients (HIV/AIDS, organ transplant recipients, chemotherapy
             patients, chronic steroid use)

          -  Patients with history of severe hypertension related illness such as hypertension
             associated with stroke or myocardial infarction

          -  Patients in who continuation of their ACE-I is expressly mandated by their
             prescribing physician
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Bolognesi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Bolognesi, MD</last_name>
    <email>michael.bolognesi@duke.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jennifer K Friend</last_name>
    <email>jennifer.friend@duke.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer K Friend</last_name>
      <email>jennifer.friend@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Bolognesi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 18, 2014</lastchanged_date>
  <firstreceived_date>May 29, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypotension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
    <mesh_term>Enzyme Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
